[go: up one dir, main page]

WO2008011487A3 - L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain - Google Patents

L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain Download PDF

Info

Publication number
WO2008011487A3
WO2008011487A3 PCT/US2007/073818 US2007073818W WO2008011487A3 WO 2008011487 A3 WO2008011487 A3 WO 2008011487A3 US 2007073818 W US2007073818 W US 2007073818W WO 2008011487 A3 WO2008011487 A3 WO 2008011487A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzyl
diamin0
propionicacid
hydr0xy
amides
Prior art date
Application number
PCT/US2007/073818
Other languages
French (fr)
Other versions
WO2008011487A2 (en
Inventor
John E Donello
Fabien J Schweighoffer
Bertrand Leblond
Original Assignee
Allergan Inc
John E Donello
Fabien J Schweighoffer
Bertrand Leblond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, John E Donello, Fabien J Schweighoffer, Bertrand Leblond filed Critical Allergan Inc
Publication of WO2008011487A2 publication Critical patent/WO2008011487A2/en
Publication of WO2008011487A3 publication Critical patent/WO2008011487A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed herein are methods of treating a patient suffering from one or more types of chronic pain using the following compounds:
PCT/US2007/073818 2006-07-19 2007-07-18 L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain WO2008011487A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80779606P 2006-07-19 2006-07-19
US60/807,796 2006-07-19

Publications (2)

Publication Number Publication Date
WO2008011487A2 WO2008011487A2 (en) 2008-01-24
WO2008011487A3 true WO2008011487A3 (en) 2008-05-15

Family

ID=38740306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073818 WO2008011487A2 (en) 2006-07-19 2007-07-18 L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain

Country Status (1)

Country Link
WO (1) WO2008011487A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2546181T3 (en) 2006-05-09 2015-09-21 Genzyme Corporation Methods of treating fatty liver disease by inhibiting the synthesis of glycosphingolipids
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
US9314466B2 (en) * 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
EP2550965B1 (en) 2007-10-05 2019-01-16 Genzyme Corporation Ceramide derivatives for treating polycystic kidney disease
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
MX2011003517A (en) 2008-10-03 2011-05-25 Genzyme Corp 2-acylaminopropoanol-type glucosylceramide synthase inhibitors.
AU2010295698A1 (en) * 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating disorders of gastrointestinal motility
WO2011034912A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating spasticity
EP3912977A1 (en) 2013-09-20 2021-11-24 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
CN109096243B (en) * 2018-07-26 2020-06-26 南京昊绿生物科技有限公司 Synthesis process of deuterated ibrutinostat racemate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720852A1 (en) * 1993-08-13 1996-07-10 Seikagaku Corporation Remedy for nervous diseases
WO2005063275A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
WO2006036512A2 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
WO2006081252A2 (en) * 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720852A1 (en) * 1993-08-13 1996-07-10 Seikagaku Corporation Remedy for nervous diseases
WO2005063275A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
WO2006036512A2 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
WO2006081252A2 (en) * 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PANNU R ET AL: "A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: implications for neuroinflammatory diseases", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 24, no. 26, 30 June 2004 (2004-06-30), pages 5942 - 5954, XP002993267, ISSN: 0270-6474 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

Also Published As

Publication number Publication date
WO2008011487A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2007087468A3 (en) Adiponectin for treatment of various disorders
EP2059282A4 (en) Apparatus, methods and devices for treatment of ocular disorders
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
EP2097012A4 (en) Devices and methods for the treatment of heart failure
SI2019683T2 (en) Administration of growth factors for the treatment of cns disorders
IL201309A0 (en) Novel n - (8 - heteroaryltetrahydronaphtalene - 2yl) or n - (5 - heteroarylchromane - 3 - yl) carboxamide derivatives for the treatment of pain
EP1951158A4 (en) Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
MX2009004134A (en) Treatment of demyelinating disorders.
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
IL193697A0 (en) Methods for treating cognitive and other disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
ZA200807357B (en) Inhibitors of PAI-1 for treatment of muscular conditions
ZA200903653B (en) Methods for treatment of cochlear and vestibular disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
WO2008011485A3 (en) Methods for treating chronic pain
EP1942909A4 (en) Methods for treating respiratory disorders
EP1951238A4 (en) Method for treating chronic pain
ZA200904478B (en) Novel therapeutic use for treating leukaemia
IL226362A0 (en) Compounds, and methods for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813080

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813080

Country of ref document: EP

Kind code of ref document: A2